Human arteries engineered in vitro
Human arteries engineered in vitro
复制标题
DOI：
10.1038/sj.embor.embor847
复制
发表时间：
2003-06-01
期刊：
影响因子：
7.7
通讯作者：
Counter, CM
中科院分区：
文献类型：
--
作者：
McKee, JA;Banik, SSR;Counter, CM
迫切需要开发用于搭桥手术的小口径动脉工程方法。我们假设，阻碍以前从非新生儿组织工程化这种血管的尝试的限速步骤是平滑肌细胞（SMC）的有限增殖能力，平滑肌细胞是这些血管的主要细胞组分。人类端粒酶逆转录酶亚基（hTERT）的异位表达最近已被证明可以延长某些人类细胞的寿命。因此，我们将hTERT导入人SMC，发现所得细胞增殖远远超过其正常寿命，但保留了正常对照SMC的特征。重要的是，使用这些非新生儿SMC，我们能够设计出机械坚固的人体血管，这是为搭桥手术创造具有临床价值的动脉的关键一步。
There is a pressing need to develop methods to engineer small-calibre arteries for bypass surgery. We hypothesized that the rate-limiting step that has thwarted previous attempts to engineer such vessels from non-neonatal tissues is the limited proliferative capacity of smooth muscle cells (SMCs), which are the main cellular component of these vessels. Ectopic expression of the human telomerase reverse transcriptase subunit ( hTERT) has been shown recently to extend the lifespan of certain human cells. We therefore introduced hTERT into human SMCs and found that the resulting cells proliferated far beyond their normal lifespan but retained characteristics of normal control SMCs. Importantly, using these non-neonatal SMCs, we were able to engineer mechanically robust human vessels, a crucial step towards creating arteries of clinical value for bypass surgery.